Piper Sandler raised the firm’s price target on ALX Oncology (ALXO) to $4 from $3 and keeps an Overweight rating on the shares following several recent updates. The firm is updating its model to reflect the financing, removed gastric/GEJ revenue, and now gives credit for HER2+ and CD47-high 2L+ breast cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology announces major underwritten public equity offering
- ALX Oncology Highlights Biomarker Data and Cash Position
- ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
- ALX Oncology Expands Inducement Equity Plan for Hiring
- ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial